Sign in
KNTE Stock Price, Chart, Stats & News
Kinnate Biopharma Inc.
Save
Kinnate Biopharma Inc. (KNTE) does not currently pay a dividend.
124.99M
Market cap
–
Current P/E
–
Forward P/E
KNTE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -64.89% |
ROE | -58.86% |
D/E | 0.02x |
Interest coverage ratio | – |
KNTE valuation
P/E | – |
P/S | – |
P/B | 0.77x |
P/CF | -1.23x |
P/FCF | -1.25x |
P/OCF | -1.23x |
PEG | -0.01x |
EV multiple | -1.51x |
About
Kinnate Biopharma Inc. is a U. S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors.
Similar securities
Based on sector and market capitalization
Report issue